Health Condition 1: C50- Malignant neoplasm of breast Health Condition 2: C34- Malignant neoplasm of bronchus andlung Health Condition 3: C53- Malignant neoplasm of cervix uteri Health Condition 4: C18- Malignant neoplasm of colon Health Condition 5: C15- Malignant neoplasm of esophagus Health Condition 6: C56- Malignant neoplasm of ovary Health Condition 7: C20- Malignant neoplasm of rectum Health Condition 8: C16- Malignant neoplasm of stomach Health Condition 9: C00-C14- Malignant neoplasms o
Conditions
Interventions
None listed
Sponsors
Strand Life Sciences Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed malignant and benign neoplasms who are eligible for surgical resection, chemotherapy or radiation treatments, as identified by the site Principal Investigator or Co-Investigators through routine clinical care processes. 2. Age- 18 years and above. 3. Patients must have normal laboratory criteria as defined below: â?? Platelets >100,000/mcL â?? PTT as per institutional limits â?? INR as per institutional limits 4. Patients who have not undergone any oncosurgery. 5. Patients who are treatment-naïve. 6. Both men and women of all races and ethnic groups are eligible for this study. 7. Ability to understand and the willingness to sign a written Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Subjects who have undergone prior chemotherapy, targeted therapy or radiation therapy 2. Subjects with recurrent or relapse cases 3. Patients who have an uncontrolled infection 4. Patients who are receiving any oncology investigational agent(s) 5. Patients who are coagulopathic and are taking blood thinning products 6. Women who are pregnant or suspect they are pregnant and lactating mothers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of signature biomarkers via a minimally invasive procedure will enable early detection of cancer, identification of markers to aid in diagnostic dilemma (distinguish between benign and malignant cases).Timepoint: Three years upon study initiation | — |
Secondary
| Measure | Time frame |
|---|---|
| Study will help in identifying high risk populationsTimepoint: After 3 years of study initiation | — |
Countries
India
Contacts
Public ContactDr Vamsi Veeramachaneni
Strand Life Sciences Private Limited
Outcome results
None listed